Please login to the form below

ferumoxytol

This page shows the latest ferumoxytol news and features for those working in and with pharma, biotech and healthcare.

Amag buys into maternal health business

Adding Makena into its portfolio will give Amag an opportunity in future to increase sales of its own flagship product Feraheme (ferumoxytol), used to treat iron-deficiency anaemia in patients with

Latest news

Death leads to recall of batch of Takeda's Rienso in Switzerland

Marketing partner Amag also reports three other hypersensitivity reactions. Takeda has recalled a batch of its anaemia medicine Rienso (ferumoxytol) in Switzerland following four reports of hypersensitivity reactions, including one death.
SMC approves Eliquis, restricts use of Rienso

Meanwhile the SMC's latest round of decisions also saw it back the restricted use of Takeda's treatment for iron deficiency anaemia in chronic kidney disease (CKD) Rienso (ferumoxytol).
Takeda’s iron deficiency drug Rienso gets EU green light

The companies carried out three phase III trials to support approval of Rienso (ferumoxytol), which showed that the drug significantly increased haemoglobin levels as compared to oral iron across the spectrum ... cent. AMAG's chief executive, William
Orphan drug focus

318. AMAG Pharmaceuticals/ Takeda. feraheme (ferumoxytol) - for iron deficiency anaemia.
Takeda to cut 10 per cent of jobs

and Feraheme (ferumoxytol) for anaemia associated with chronic renal failure.

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

Interview: Trevor Smith, Takeda

iron deficiency anaemia treatment Rienso (ferumoxytol) in June.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Spectrum appoints chief medical officer

2013. The appointment is a return to oncology for Dr Allen following a six-year spell as chief medical officer at AMAG Pharmaceuticals – the developer of Feraheme (ferumoxytol) for the treatment

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Medical Strategic Director, Healthcare Advertising Agency: Salary TBC

Healthcare Advertising Account Manager / Senior AM / AD: Salary TBC

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Healthcare PR Director: £100, 000 – £120, 000 benefits

Account Manager, Healthcare Advertising: Salary TBC

Senior Account Executive – Medical Communications: Salary TBC

Senior Account Manager / Account Director - Med Comms: Great salary and benefits

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Account Manager- Manchester, Macclesfield or Glasgow: Negotiable

Director – Head of Public Affairs: Neg

Account Manager, Healthcare Communications: £32, 000 - £40, 000 benefits

Lead Medical Copywriter, Healthcare Brand Communications, London: Excellent package

Scientific Director: Highly Competitive Salary &Benefits

Scientific Team Lead: Competitive Salary

Associate Medical Director: Highly Competitive

Experienced Editor, London, Medical Communications: Competitive package

Project / Account Manager (Medical Education): Salary TBC

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Account Director: Negotiable

Account Director - Digital: Great salary and benefits

Account Director – Global Healthcare PR: Salary TBC

Associate Medical Director: Salary TBC

Editorial Director – Medical Education: Neg

Senior Account Manager - Med Comms: Highly Competitive Salary &Benefits

Subscribe to our email news alerts

PMHub

Add my company

Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies: Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?: Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds: A vision of Paris as Europe’s leading hub for life sciences innovation...